Trials / Completed
CompletedNCT02387814
A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
A Single-Dose Pharmacokinetic Study of Abemaciclib (LY2835219) in Subjects With Varying Degrees of Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when given to participants with mild, moderate, or severe liver impairment compared to healthy participants. In addition, the tolerability of the study drug will be evaluated. This study will last approximately 3 weeks for each participant, including check-in and follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Administered Orally |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2015-03-13
- Last updated
- 2019-03-05
- Results posted
- 2019-01-22
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02387814. Inclusion in this directory is not an endorsement.